At a recent American Society for Clinical Oncology (ASCO) conference investors were able to review progress in immunotherapy clinical trials. The progress is positive. Incyte, for one, presented improved patient response rates in five types of cancer...
Daniel Koller, BB Biotech's head of investment, discusses sector growth, innovation and the attractive valuations of fast-growing companies.
Equity markets performed well in the first quarter driven by an expectation of lower corporate tax rates in the US and the potential repatriation of offshore cash and investments in infrastructure.
Look for companies exploiting new technologies
More support needed for UK innovation
QuotedData monthly roundup
Criticised pricing policies
Opportunities in a number of sectors
The end of a 35-year bond bull market, the rise of so-called robojobs, rapid developments in gene editing and the 'sharing economy' will be among the themes that will interest investors next year and beyond, according to Investec Wealth & Investment's...
Rallied following Clinton defeat
US govt likely to be supportive of biomedical research
Boosted by Trump's win
As the most exciting US Presidential race in decades reaches its conclusion, three fund managers from Pioneer Investments give their views on the implications for different asset classes.
Subject to shareholder approval
Latest roundup by QuotedData
Chris Smith, analyst - Japanese equities at Polar Capital, discusses the evolution of the Japanese market and the search for income.
Overuse of antibiotics around the globe has created a worrying increase in resistance to many commonly used drugs, writes Carl Harald Janson, lead manager on the International Biotechnology trust.
With all three rating agencies lowering growth expectations for the domestic economy following the referendum result last month, the attractions of investing for long-term growth in the technology related sectors has again been highlighted in our view....
Trump and Clinton fight for presidency
Founding partner of Sloane Robinson
Healthcare was one sector that did not fully participate in the recent stockmarket rally and finished the first quarter as the worst performer in the S&P 500 index, writes Legg Mason's Evan Bauman.
Shares dropped 90% since summer
The pharmaceutical and biotechnology sector has performed well in recent years, primarily by virtue of attractive fundamentals.
Gold funds top performance charts